NCT06761677 - A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

October 23, 2027

Study Completion Date

May 8, 2029

Conditions

Relapsed or Refractory Lymphoma Including ENKL

Interventions

DRUG

Brincidofovir

Phase 1b part is dose escalation study evaluating three dose levels of BCV, and participants will be assigned to a dose schedule in the order of study entry. In Phase 2 part, participants will receive BCV BIW at the RP2D (determined in the Phase 1b part).

Trial Locations (8)

Unknown

RECRUITING

Queen Mary Hospital, Hong Kong

RECRUITING

Tokyo Metropolitan Komagome Hospital, Bunkyō City

RECRUITING

National Cancer Center Hospital, Chūōku

RECRUITING

Cancer Institute Hospital Of JFCR, Kōtoku

RECRUITING

Kyoto University Hospital, Kyoto

RECRUITING

Okayama University Hospital, Okayama

RECRUITING

Mie University Hospital, Tsu

RECRUITING

National Cancer Centre Singapore, Singapore